Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY162016-06-30 | Q1 FY162016-03-31 | Q4 FY152015-12-31 | Q3 FY152015-09-30 | Q2 FY152015-06-30 | Q1 FY152015-03-31 | Q4 FY142014-12-31 | Q3 FY142014-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.60B | $6.12B | $6.40B | $5.95B | $6.31B | $6.06B | $6.72B | $6.61B |
| Cost of revenue | $1.15B | $1.08B | $1.37B | $1.12B | $1.15B | $1.35B | $1.76B | $1.50B |
| Gross profit | $4.45B | $5.04B | $5.03B | $4.83B | $5.16B | $4.71B | $4.96B | $5.11B |
| Gross margin | 79.4% | 82.3% | 78.6% | 81.2% | 81.8% | 77.8% | 73.9% | 77.3% |
| Research and development | $1.47B | $1.48B | $1.75B | $1.43B | $1.47B | $1.36B | $1.50B | $1.55B |
| Selling, general and administrative | $3.05B | $2.57B | $2.67B | $2.68B | $2.97B | $2.80B | $4.08B | $3.13B |
| Operating expenses | $4.15B | $4.00B | $3.94B | $3.66B | $4.23B | $3.78B | $5.31B | $4.57B |
| Operating income | $303.00M | $1.04B | $1.09B | $1.17B | $923.00M | $933.00M | −$349.00M | $541.00M |
| Operating margin | 5.4% | 17.0% | 17.0% | 19.7% | 14.6% | 15.4% | -5.2% | 8.2% |
| EBITDA | $890.00M | $1.61B | $1.09B | $1.74B | $1.64B | $1.78B | −$349.00M | $1.39B |
| Interest income | $17.00M | $14.00M | $13.00M | $9.00M | $13.00M | $11.00M | $33.00M | $19.00M |
| Interest expense | −$342.00M | −$325.00M | −$292.00M | −$246.00M | −$276.00M | −$261.00M | −$260.00M | −$236.00M |
| Income before taxes | −$30.00M | $723.00M | $802.00M | $931.00M | $658.00M | $678.00M | −$580.00M | $322.00M |
| Income taxes | $1.00M | $98.00M | −$6.00M | $161.00M | −$38.00M | $126.00M | −$259.00M | $69.00M |
| Net income | −$31.00M | $625.00M | $808.00M | $770.00M | $696.00M | $552.00M | −$321.00M | $253.00M |
| Net margin | -0.6% | 10.2% | 12.6% | 13.0% | 11.0% | 9.1% | -4.8% | 3.8% |
| EPS, basic | $0.00 | $0.51 | $0.63 | $0.61 | $0.55 | $0.44 | −$0.25 | $0.20 |
| EPS, diluted | $0.00 | $0.51 | $0.64 | $0.60 | $0.55 | $0.44 | −$0.25 | $0.20 |
| Diluted shares | 1.27B | 1.27B | 1.27B | 1.27B | 1.27B | 1.27B | 1.26B | 1.26B |
Figures describe AstraZeneca shares, not any token. As of Feb 24, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.